Q-omics provides the consensus-scored SNORD12C profile across patient tissues and cancer cell-line models. SNORD12C expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SNORD12C is differentially expressed in 11, with the highest sampling consensus in STAD. Additionally, SNORD12C RNA expression shows 10,723 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight UVM, STAD, and LUAD as cancer lineages where SNORD12C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD12C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD12C survival associations across molecular data types. SNORD12C RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD12C RNA expression–survival associations across cancer types. High SNORD12C expression shows unfavorable associations in UVM, STAD, KIRC and MESO, but favorable associations in BRCA and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SNORD12C RNA expression.
This table summarizes SNORD12C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD12C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD12C shows higher tumor expression in STAD, COAD, BLCA, UCEC, BRCA and KIRC. The STAD box plot shows higher SNORD12C RNA expression in tumor versus normal tissue (log2 FC = +1.312, t-test p < 0.001).
This table shows molecular features associated with SNORD12C in patient tissues and cancer cell lines. In patient samples, SNORD12C shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
